MannKind Corporation
MNKDHealthcareNASDAQBiotechnology · Last scanned Jul 16, 2026
Scan Results
Daily timeframeMannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. The $1.26B market capitalization puts MNKD squarely in small-cap range for its industry. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Market Cap
$1.26B
Beta
1.09
P/E (TTM)
—
P/E (Fwd)
21.25
EPS (TTM)
$-0.07
EPS (Fwd)
$0.19
ROE
—
ROA
2.0%
Cash
$133.9M
Total Debt
$434.2M
Free CF
$47.0M
52W Change
3.3%
Annual Financials
Cash vs Debt
On the balance sheet, MNKD has $133.9M in cash with $434.2M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $47.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROA of 2.0% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $99.8M (2022) to $349.0M (2025), reflecting a 250% increase over the period.
As with any equity investment, MNKD carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence MannKind Corporation's trajectory.